Intelligent Ultrasound Group PLC Intelligent Ultrasound signs research agreement (5510S)
November 07 2023 - 1:00AM
UK Regulatory
TIDMIUG
RNS Number : 5510S
Intelligent Ultrasound Group PLC
07 November 2023
Intelligent Ultrasound signs research agreement with University
of Dundee to develop AI-based diagnostic tools for liver
disease
PRESS RELEASE 07 November 2023: Intelligent Ultrasound Group plc
(AIM: IUG), the 'classroom to clinic' ultrasound company,
specialising in artificial intelligence (AI) software and
simulation, is pleased to announce that it has signed a research
agreement with the University of Dundee to initiate the first phase
of proof-of-concept work to develop AI-based tools for screening
patients with liver disease.
Utilising the comprehensive archive comprising over one million
ultrasound images from approximately 50,000 patients from the
University of Dundee and NHS Tayside, the Intelligent Ultrasound
team intends to create machine-learning models that make it easier
to stage liver disease and monitor disease progression.
The agreement, which is mainly royalty-based, will allow
Intelligent Ultrasound to develop ultrasound-based AI tools with
the potential to support clinicians in the clinical management of
metabolic dysfunction-associated steatotic liver disease (MASLD)
and its advanced form, metabolic dysfunction-associated
steatohepatitis (MASH). MASLD is the leading cause of liver disease
and is closely related to obesity, the rates of which are rising.
[1] Monitoring MASLD is important as patients in the early stages
of the disease may be able to reduce the effects on their liver
with dietary and lifestyle changes if caught in time. [2]
Around 30% of the world's population have MASLD, and by 2030 it
is expected that healthcare systems will need to accurately stage
the disease to allow them to target treatment. [3] As current
methods for diagnosis are either invasive, costly, or inaccurate,
it is hoped that AI-based ultrasound may prove to be a
cost-effective point of care technique that can give clinicians the
answers they need.
Nicholas Sleep, COO at Intelligent Ultrasound said:
"We are very pleased to be working with Prof. John Dillon at the
University of Dundee on this exciting project. John is a
world-renowned hepatologist, having played a major role in
introducing Hepatitis C screening in Scotland. His team's clinical
experience, combined with the richness of the Dundee dataset,
create a strong pairing with Intelligent Ultrasound's expertise in
creating healthcare AI solutions. This is a key longer-term step
for us as we look to build our fourth AI ultrasound platform and we
have high hopes for this proof-of-concept work."
Professor John Dillon, Professor of Hepatology and
Gastroenterology, Clinical Professor (Teaching and Research) of
Hepatology and Gastroenterology, Molecular and Clinical Medicine at
the University of Dundee said:
"One of the largest challenges facing us in medicine today is
how to stratify a disease - MASLD - that affects 30% of the global
population and find the much smaller group with MASH who are at
high risk of complications. I am optimistic that by working with
the AI specialists at Intelligent Ultrasound, we may be able to
make the widely available ultrasound scanning facilities much more
useful by adding the ability to differentiate MASH from MASLD
patients."
ENDS
Enquiries:
Intelligent Ultrasound Group plc www.intelligentultrasound.com
Stuart Gall, CEO Tel: +44 (0)29 2075 6534
Helen Jones, CFO
Cavendish Securities Plc
(Nominated advisor and broker)
Giles Balleny (Corporate Finance) Tel: +44 (0)20 7397 8900
Dale Bellis (Sales)
TB Cardew - PR Advisors Intelligentultrasound@tbcardew.com
Ed Orlebar Tel: +44 (0)7738 724630
Allison Connolly Tel: +44 (0)7587 453955
Emma Pascoe-Watson Tel: +44 (0)7774 620415
Hero Kurzeja Tel: +44 (0)7827 130430
About Intelligent Ultrasound Group
Intelligent Ultrasound (AIM: IUG) is one of the world's leading
'classroom to clinic' ultrasound companies, specialising in
real-time hi-fidelity virtual reality simulation for the ultrasound
training market ('classroom') and artificial intelligence-based
clinical image analysis software tools for the diagnostic medical
ultrasound market ('clinic'). Based in Cardiff in the UK and
Atlanta in the US, the Group has two revenue streams:
Simulation
Real-time hi-fidelity ultrasound education and training through
simulation. Our main products are the ScanTrainer obstetrics and
gynaecology training simulator, the HeartWorks echocardiography
training simulator, the BodyWorks Eve Point of Care and Emergency
Medicine training simulator with Covid-19 module and the new
BabyWorks Neonate and Paediatric training simulator. To date over
1,500 simulators have been sold to over 750 medical institutions
around the world.
Clinical AI software
Deep learning-based algorithms to make ultrasound machines
smarter and more accessible using our proprietary ScanNav
ultrasound image analysis technology. Current products on the
market utilising this technology are GE Healthcare's SonoLyst
software that is incorporated in their Voluson Expert 22 and SWIFT
ultrasound machines; ScanNav Anatomy PNB that simplifies
ultrasound-guided needling by providing the user with real-time
AI-based
anatomy highlighting for a range of medical procedures; and NeedleTrainer that teaches real-time ultrasound-guided needling and incorporates ScanNav Anatomy PNB.
www.intelligentultrasound.com
NOTE: ScanNav Anatomy PNB is CE approved and cleared for sale in
the US by the FDA, but is not available for sale in any other
territory requiring government approval for this type of
product.
[1] Fatty Liver Disease (liverfoundation.org)
[2] NAFLD, NASH and fatty liver disease - British Liver
Trust
[3] " The global epidemiology of nonalcoholic fatty liver
disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a
systematic review". Heptaology, April 2023, 77(4), 1335-1347
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGRUPGQWGUPWGMQ
(END) Dow Jones Newswires
November 07, 2023 02:00 ET (07:00 GMT)
Intelligent Ultrasound (LSE:IUG)
Historical Stock Chart
From Apr 2024 to May 2024
Intelligent Ultrasound (LSE:IUG)
Historical Stock Chart
From May 2023 to May 2024